Research Analysts Issue Forecasts for BOLT Q1 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of Bolt Biotherapeutics in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White expects that the company will earn ($0.33) per share for the quarter. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.34) EPS.

Separately, Stifel Nicolaus cut their price objective on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Bolt Biotherapeutics has a consensus rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Trading Down 3.3 %

Shares of BOLT stock opened at $0.43 on Friday. Bolt Biotherapeutics has a 1 year low of $0.38 and a 1 year high of $1.56. The firm has a market capitalization of $16.29 million, a PE ratio of -0.25 and a beta of 0.94. The stock has a fifty day moving average of $0.47 and a two-hundred day moving average of $0.55. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million.

Hedge Funds Weigh In On Bolt Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Citadel Advisors LLC acquired a new stake in shares of Bolt Biotherapeutics in the fourth quarter valued at $42,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics during the fourth quarter worth about $27,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter worth about $26,000. Millennium Management LLC acquired a new stake in Bolt Biotherapeutics in the 4th quarter valued at about $25,000. Finally, FMR LLC boosted its position in shares of Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares in the last quarter. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.